Immunotherapy, Active

• 

  Subject Areas on Research

  • A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. 
  • A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. 
  • A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. 
  • Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. 
  • Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers. 
  • Active-specific immunization against melanoma: is the problem at the receiving end? 
  • Adoptive immunotherapy for malignant glioma. 
  • Advanced prostate cancer: the future. 
  • Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. 
  • Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1: Report from a meeting of the WHO-UNAIDS Vaccine Advisory Committee Geneva, 21-23 February 2000. 
  • Assays for monitoring cellular immune responses to active immunotherapy of cancer. 
  • Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. 
  • CD19: a promising B cell target for rheumatoid arthritis. 
  • Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. 
  • Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. 
  • DNA and RNA modified dendritic cell vaccines. 
  • Disrupting nicotine reinforcement: from cigarette to brain. 
  • EGFRvIII as a promising target for antibody-based brain tumor therapy. 
  • Experimental trials of immunotherapy for malignant melanoma. 
  • Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. 
  • Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. 
  • How does sipuleucel-T alter our clinical practice? 
  • Human immunodeficiency virus vaccines. 
  • Immunotherapy for malignant melanoma with a tumor cell vaccine. 
  • Immunotherapy of cancer using dendritic cells. 
  • Immunotherapy of cancer with dendritic cell-based vaccines. 
  • Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. 
  • Preparation of peptide-loaded dendritic cells for cancer immunotherapy. 
  • Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. 
  • Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. 
  • Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. 
  • Tumor microenvironment and the immune response. 
  • Tumors as elusive targets of T-cell-based active immunotherapy. 
  • Vaccine Therapy, Oncolytic Viruses, and Gliomas. 
• 

  Keywords of People

  • Fecci, Peter Edward, Associate Professor of Neurosurgery, Immunology